APAC Cancer Biological Therapy Companies

Biocon acquires Viatris' biosimilar insulin portfolio: November 2023 deal strengthens Biocon's presence in the diabetes care market and expands access to affordable insulin options in the region.

AstraZeneca partners with Chinese biotech companies: AstraZeneca is actively forging partnerships with local players like Jiangsu Hengrui Medicine and Mabtech to develop and commercialize innovative cancer drugs for the Asian market.

Roche launches Tecentriq (atezolizumab) for first-line non-small cell lung cancer in Japan: December 2023 approval expands treatment options for lung cancer patients in Japan.

Eli Lilly receives China approval for Verzenio (abemaciclib) for metastatic breast cancer: October 2023 approval opens up access to a targeted therapy for Chinese patients with advanced breast cancer.

List of Asia Pacific Cancer Biological Therapy Key Companies in the Market

• Merck & Co. Inc. (US)


• Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Amgen Inc. (US)


• Bristol-Myers Squibb (US)


• Celgene (US)


• Eli Lilly and Company (US)


• EnGeneIC (Australia)


• Pfizer (US)


• Intas Pharmaceuticals Ltd. (India)


• Sun Pharmaceutical Industries Ltd. (India)